<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 35-year-old male presented with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (CMMoL) after 6.5 years of <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> therapy for IgG-kappa type <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The total dose of melphalan was 0.648 g </plain></SENT>
<SENT sid="2" pm="."><plain>CMMoL was stable with weekly injection of alpha-interferon for one year </plain></SENT>
<SENT sid="3" pm="."><plain>Thereafter, <z:mp ids='MP_0000220'>monocytosis</z:mp> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> aggravated, and the patient died of disseminating intravascular coagulation </plain></SENT>
<SENT sid="4" pm="."><plain>Prolonged drug therapy can induce CMMoL, as well as other <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
</text></document>